EBITDA increased by 14% to RON61.7 million.
In the first half of 2025, the company consolidated its second position in the Consumer Healthcare (CHC) segment, based on the number of units sold. Sales growth was supported by increases recorded by brands dedicated to digestive health, pain management, symptomatic treatment of colds and flu, as well as products targeting stress and anxiety, Biofarm says in its report.
(English version by Loredana Fratila-Cristescu)